Showing results (171-180 of 223) with videos related to
Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2019
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 ActivationPatricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, et al.Cancer Medicine|February 28, 2015
HER2 as a target in invasive urothelial carcinomaJoaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.The Oncologist|July 14, 2017
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker AnalysisMiguel Martín, José I Chacón, Antonio Antón, et al.Journal of Experimental & Clinical Cancer Research : CR|January 3, 2024
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancerSara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, et al.Peerj|October 21, 2020
Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignanciesIván Prieto-Potin, Nerea Carvajal, Jenifer Plaza-Sánchez, et al.Cell Death and Differentiation|March 10, 2023
Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cellsSara S Oltra, Sara Colomo, Laura Sin, et al.Molecular Oncology|January 11, 2019
Molecular evidence of field cancerization initiated by diabetes in colon cancer patientsLaura Del Puerto-Nevado, Pablo Minguez, Marta Corton, et al.Virchows Archiv : an International Journal of Pathology|April 3, 2024
Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology AssessmentsJosef Rüschoff, George Kumar, Sunil Badve, et al.The Oncologist|January 21, 2016
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast CancerEmilio Alba, Ana Lluch, Nuria Ribelles, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant CapecitabineKarama Asleh, Ana Lluch, Angela Goytain, et al.Pageof 23